Download PDF
Exp Clin Endocrinol Diabetes 2021; 129(01): 36-42
DOI: 10.1055/a-0723-3749
Article

Association of Irisin Circulating Level with Diabetic Retinopathy: A Case-Control Study

Nafez Abu Tarboush
1   Department of Biochemistry and Physiology, Amman, Jordan
3   School of Medicine, The University of Jordan, Amman, Jordan
,
Nakhleh E Abu-Yaghi
2   Department of Special surgery – Ophthalmology division, Amman, Jordan
3   School of Medicine, The University of Jordan, Amman, Jordan
,
Laith H Al Ejeilat
3   School of Medicine, The University of Jordan, Amman, Jordan
,
Rawand K. Abdel Wahed
3   School of Medicine, The University of Jordan, Amman, Jordan
,
Issa N Jeris
2   Department of Special surgery – Ophthalmology division, Amman, Jordan
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Abstract

Obesity and obesity induced type 2 diabetes development and progression have been associated with sedentary lifestyle. Irisin, a newly discovered myokine, has been demonstrated at lower levels in obese and type 2 diabetes patients compared to controls. The main aim of this study is to explore association of Irisin with diabetic retinopathy (DR). A total of 233 healthy and adults participated in this study. Participants were divided into four categories: a healthy control group and an age-match subset of patients with type 2 diabetes; a positive control group of patients with type 2 diabetes not affected by DR (No DR); and patients with type 2 diabetes affected by DR (non-proliferative DR (NPDR) and proliferative DR (PDR)). Plasma samples were quantified for Irisin measurement, lipid profile and HbA1c. Comparison of the age-matched groups of healthy controls and patients with type 2 diabetes revealed lower Irisin plasma level in type 2 diabetes group. Analyses revealed negative correlations of Irisin to HbA1c and LDL levels and positive correlation to HDL level. Comparing Irisin level in No DR and DR groups revealed a higher level in No DR group and analysis per DR classification indicated higher Irisin level in NPDR group. Our results demonstrate not only correlation of plasma Irisin level with DR stages, but also significantly different Irisin level among them. This is promising in terms of researching Irisin as a potential associating marker for type 2 diabetes and DR development and progression.

Key words

irisin - diabetes - diabetic retinopathy - metabolism - adipose tissue


Publication History

Received: 15 June 2018
Received: 30 July 2018

Accepted: 29 August 2018

Article published online:
17 September 2018

© 2020. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Hossain P, Kawar B, El Nahas M. Obesity and diabetes in the developing world—a growing challenge. N Engl J Med 2007; 356: 213-215
    CrossrefPubMedGoogle Scholar
  • 2 Bjørge T, Engeland A, Tverdal A. Body mass index in adolescence in relation to cause-specific mortality: a follow-up of 230,000 Norwegian adolescents. Am J Epidemiol 2008; 168: 30-37
    CrossrefPubMedGoogle Scholar
  • 3 World Health Organization. Obesity and overweight. Retrieved from http://www.who.int/mediacentre/factsheets/en/ 2016;
    PubMed
  • 4 World Health Organization. Prevalence of Obesity by Country. Retrieved from http://www.who.int/mediacentre/factsheets/en/ 2014;
    PubMed
  • 5 Brownlee M. The pathobiology of diabetic complications: A unifying mechanism. Diabetes 2005; 54: 1615-1625
    CrossrefPubMedGoogle Scholar
  • 6 Nentwich MM, Ulbig MW. Diabetic retinopathy—ocular complications of diabetes mellitus. World J Diabetes 2015; 6: 489-499
    CrossrefPubMedGoogle Scholar
  • 7 International Diabetes Federation. IDF Diabetes Atlas. 8th edn Brussels, Belgium Retrieved from: http://www.diabetesatlas.org 2015
    Google Scholar
  • 8 Frank RN. The Galactosemic Dog - a valid model for both early and late stages of diabetic-retinopathy. Arch Ophthalmol 1995; 113: 275-276
    CrossrefPubMedGoogle Scholar
  • 9 Crick RP, Khaw PT. The Retina. A textbook of clinical ophthalmology: a practical guide to disorders of the eyes and their management. New Jersey: World Scientific Publishing Co Inc.; 2003: 517-533
    CrossrefGoogle Scholar
  • 10 Pieczynski J, Grzybowski A. Review of diabetic retinopathy screening methods and programs adopted in different parts of the world. European Ophthalmic Review 2015; 9: 49-55
    CrossrefPubMedGoogle Scholar
  • 11 Zorena K, Raczynska D, Raczynska K. Biomarkers in diabetic retinopathy and the therapeutic implications. Mediators of inflammation 2013 Article ID 193604, 11 pages, 2013
    PubMed
  • 12 Duh E, Aiello LP. Vascular endothelial growth factor and diabetes: the agonist versus antagonist paradox. Diabetes 1999; 48: 1899-1906
    CrossrefPubMedGoogle Scholar
  • 13 Jusufbegovic D, Mugavin MO, Schaal S. Evolution of controlling diabetic retinopathy: Changing trends in the management of diabetic macular edema at a single institution over the past decade. Retina 2015; 35: 929-934
    CrossrefPubMedGoogle Scholar
  • 14 Kriechbaum K, Prager S, Mylonas G. et al. Intravitreal bevacizumab (Avastin) versus triamcinolone (Volon A) for treatment of diabetic macular edema: one-year results. Eye (Lond) 2014; 28: 9-15
    CrossrefPubMedGoogle Scholar
  • 15 Schneider S, Ruderman N. Exercise and NIDDM (technical review). Diabetes care 1990; 13: 785-789
    CrossrefPubMedGoogle Scholar
  • 16 Horton ES. Exercise and physical training: effects on insulin sensitivity and glucose metabolism. Diabetes Metab Rev 1986; 2: 1-17
    CrossrefPubMedGoogle Scholar
  • 17 Reusch JE. Focus on insulin resistance in type 2 diabetes: therapeutic implications. Diabetes Educ 1998; 24: 188-193
    CrossrefPubMedGoogle Scholar
  • 18 Castillo-Quan JI. From white to brown fat through the PGC-1α-dependent myokine irisin: implications for diabetes and obesity. Dis Model Mech 2012; 5: 293-295
    CrossrefPubMedGoogle Scholar
  • 19 Bostrom P, Wu J, Jedrychowski MP. et al. A PGC1-alpha-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature 2012; 481: 463-468
    CrossrefPubMedGoogle Scholar
  • 20 Wenz T, Rossi SG, Rotundo RL. et al. Increased muscle PGC-1α expression protects from sarcopenia and metabolic disease during aging. Proc Natl Acad Sci USA 2009; 106: 20405-20410
    CrossrefPubMedGoogle Scholar
  • 21 Handschin C, Spiegelman BM. The role of exercise and PGC1α in inflammation and chronic disease. Nature 2008; 454: 463-469
    CrossrefPubMedGoogle Scholar
  • 22 Liu J. Irisin as an exercise-stimulated hormone binding crosstalk between organs. Eur Rev Med Pharmacol Sci 2015; 19: 316-321
    PubMedGoogle Scholar
  • 23 Cannon B, Nedergaard J. Brown adipose tissue: function and physiological significance. Physiol Rev 2004; 84: 277-359
    CrossrefPubMedGoogle Scholar
  • 24 Huh JY, Panagiotou G, Mougios V. et al. FNDC5 and irisin in humans: I. Predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to weight loss and exercise. Metabolism 2012; 61: 1725-1738
    CrossrefPubMedGoogle Scholar
  • 25 Sanchis-Gomar F, Lippi G, Mayero S. et al. Irisin: A new potential hormonal target for the treatment of obesity and type 2 diabetes. J Diabetes 2012; 4: 196-196
    CrossrefPubMedGoogle Scholar
  • 26 Wu J, Spiegelman BM. Irisin ERKs the Fat. Diabetes 2014; 63: 381-383
    CrossrefPubMedGoogle Scholar
  • 27 Moreno-Navarrete JM, Ortega F, Serrano M. et al. Irisin is expressed and produced by human muscle and adipose tissue in association with obesity and insulin resistance. J Clin Endocrinol Metab 2013; 98: E769-E778
    CrossrefPubMedGoogle Scholar
  • 28 Liu JJ, Wong MD, Toy WC. et al. Lower circulating irisin is associated with type 2 diabetes mellitus. J Diabetes Complications 2013; 27: 365-369
    CrossrefPubMedGoogle Scholar
  • 29 Liu JJ, Liu S, Wong MD. et al. Relationship between circulating irisin, renal function and body composition in type 2 diabetes. J Diabetes Complications 2014; 28: 208-213
    CrossrefPubMedGoogle Scholar
  • 30 Zhang Y, Li R, Meng Y. et al. Irisin stimulates browning of white adipocytes through mitogen-activated protein kinase p38 MAP kinase and ERK MAP kinase signaling. Diabetes 2014; 63: 514-525
    CrossrefPubMedGoogle Scholar
  • 31 Xiang L, Xiang G, Yue L. et al. Circulating irisin levels are positively associated with endothelium-dependent vasodilation in newly diagnosed type 2 diabetic patients without clinical angiopathy. Atherosclerosis 2014; 235: 328-333
    CrossrefPubMedGoogle Scholar
  • 32 Choi YK, Kim MK, Bae KH. et al. Serum irisin levels in new-onset type 2 diabetes. Diabetes Res Clin Pract 2013; 100: 96-101
    CrossrefPubMedGoogle Scholar
  • 33 Assyov Y, Gateva A, Tsakovaet A. et al. Irisin in the glucose continuum. Exp Clin Endocrinol Diabetes 2016; 124: 22-27
    Article in Thieme ConnectPubMedGoogle Scholar
  • 34 Hu W, Wang R, Li J. et al. Association of irisin concentrations with the presence of diabetic nephropathy and retinopathy. Ann Clin Biochem 2016; 53: 67-74
    CrossrefPubMedGoogle Scholar
  • 35 Rana KS, Arif M, Hill EJ. et al. Plasma irisin levels predict telomere length in healthy adults. Age (Dordr) 2014; 36: 995-1001
    CrossrefPubMedGoogle Scholar
  • 36 Zhang W, Chang L, Zhang C. et al. Irisin: A myokine with locomotor activity. Neurosci Lett 2015; 595: 7-11
    CrossrefPubMedGoogle Scholar
  • 37 Wu J, Boström P, Sparks LM. et al. Beige adipocytes are a distinct type of thermogenic fat cell in mouse and human. Cell 2012; 150: 366-376
    CrossrefPubMedGoogle Scholar
  • 38 Oelmann S, Nauck M, Völzke H. et al. Circulating irisin concentrations are associated with a favourable lipid profile in the general population. PLoS One 2016; 11: e0154319
    CrossrefPubMedGoogle Scholar
  • 39 Ebert T, Focke D, Petroff D. et al. Serum levels of the myokine irisin in relation to metabolic and renal function. Eur J Endocrinol 2014; 170: 501-506
    CrossrefPubMedGoogle Scholar
  • 40 Wen MS, Wang CY, Lin SL. et al. Decrease in irisin in patients with chronic kidney disease. PLoS One 2013; 8: e64025
    CrossrefPubMedGoogle Scholar
  • 41 Zhu G, Wang J, Song M. et al. Irisin increased the number and improved the function of endothelial progenitor cells in diabetes mellitus mice. J Cardiovasc Pharmacol 2016; 68: 67-73
    CrossrefPubMedGoogle Scholar
  • 42 Li Z, Wang G, Zhu Y. et al. The relationship between circulating irisin levels and tissues AGE accumulation in type 2 diabetes patients. Biosci Rep 2017; 37: BSR20170213
    CrossrefPubMedGoogle Scholar
  • 43 Jenkins A, Joglekar MV, Hardikar AA. et al. Biomarkers in diabetic retinopathy. Rev Diabet Stud 2014; 12: 159-195
    CrossrefPubMedGoogle Scholar
  • 44 Ozturk BT, Bozkurt B, Kerimogluet H. et al. Effect of serum cytokines and VEGF levels on diabetic retinopathy and macular thickness. Mol Vis 2009; 15: 1906-1914
    PubMedGoogle Scholar
  • 45 Gouni-Berthold I, Berthold HK, Huh JY. et al. Effects of lipid-lowering drugs on irisin in human subjects in vivo and in human skeletal muscle cells ex vivo. PLoS One 2013; 8: e72858
    CrossrefPubMedGoogle Scholar